Related Experiment Video
Updated: Jan 13, 2026
Preparing a Mice Model of Severe Acute Pancreatitis via a Combination of Caerulein and Lipopolysaccharide Intraperitoneal Injection
Published on: May 10, 2024
Baicalin Mitigates Pasteurella multocida-Induced Pulmonary and Vascular Injury via NLRP3/COX-2 Inhibition in Mice
Dan Zhang1,2, Chengzhuo Zhao1,2, Yunda Xue1,2
1Hubei Key Laboratory of Animal Nutrition and Feed Science, School of Animal Science and Nutritional Engineering, Wuhan Polytechnic University, Wuhan 430023, China.
Abstract:
Pasteurella multocida (P. multocida), a zoonotic bacterium, is one of the most common respiratory pathogens in animal husbandry and causes many public health problems. Infection by P. multocida can cause hemorrhagic pneumonia and induce pulmonary and even vascular inflammatory injury. Baicalin has protective and/or therapeutic effects in a variety of lung diseases. However, whether it also protects against vascular inflammatory injury caused by P. multocida infection in vivo remains to be investigated. The present study used mice infected with P. multocida as a model to explore the alleviation of pulmonary and vascular inflammatory injury by baicalin. Baicalin significantly reduced weight loss, improved the pathological changes of lung and blood vessels, and reduced the expression of the inflammation-related proteins NLRP3, COX-2, IL-1β, and IL-18 in lung and blood vessel tissues. The signal inhibition of NLRP3 and COX-2 may be a key therapeutic pathway to treat P. multocida-induced pulmonary and vascular inflammatory injury. These findings suggest that baicalin inhibits the activation of inflammation to protect pulmonary and vascular injury in vivo. Hence, baicalin exhibits therapeutic potential in the treatment of pulmonary and vascular injury.
Insights
Baicalin effectively treats lung and vascular inflammation caused by Pasteurella multocida (P. multocida) infection. This study shows baicalin protects against P. multocida-induced injury by inhibiting key inflammatory pathways.
Area of Science:
- Bacteriology
- Immunology
- Pharmacology
Background:
- Pasteurella multocida (P. multocida) is a zoonotic bacterium causing respiratory disease and public health issues.
- P. multocida infection can lead to hemorrhagic pneumonia and inflammatory injury in pulmonary and vascular tissues.
- Baicalin is known for its protective effects in various lung diseases, but its role in P. multocida-induced vascular injury is unexplored.
Purpose of the Study:
- To investigate the protective effects of baicalin against P. multocida-induced pulmonary and vascular inflammatory injury in a mouse model.
- To explore the potential therapeutic mechanisms of baicalin in mitigating inflammation.
Main Methods:
- A mouse model was established by infecting with P. multocida.
- Mice were treated with baicalin to assess its therapeutic effects.
- Pathological changes in lung and blood vessels were evaluated.
- The expression of inflammation-related proteins (NLRP3, COX-2, IL-1β, IL-18) was measured in lung and blood vessel tissues.
Main Results:
- Baicalin treatment significantly reduced weight loss in infected mice.
- Pathological damage to lung and blood vessels was improved by baicalin.
- Baicalin decreased the expression of NLRP3, COX-2, IL-1β, and IL-18 in lung and vascular tissues.
- Inhibition of NLRP3 and COX-2 signaling pathways was observed.
Conclusions:
- Baicalin demonstrates significant therapeutic potential in protecting against P. multocida-induced pulmonary and vascular inflammatory injury.
- The anti-inflammatory effects of baicalin, particularly the inhibition of NLRP3 and COX-2, are key mechanisms for its protective action.
- Baicalin offers a promising therapeutic strategy for treating inflammation-related lung and vascular damage.
